title: Potential target antigens for a universal vaccine in epithelial ovarian cancer.
abstract: The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a "universal" vaccine strategy. We determined the expression of tumor antigens in the context of MHC class I expression in 270 primary tumor samples using tissue microarray. Expression of tumor antigens p53, SP17, survivin, WT1, and NY-ESO-1 was observed in 120 (48.0%), 173 (68.9%), 208 (90.0%), 129 (56.3%), and 27 (11.0%) of 270 tumor specimens, respectively. In 93.2% of EOC, at least one of the investigated tumor antigens was (over)expressed. Expression of MHC class I was observed in 78.1% of EOC. In 3 out 4 primary tumors, (over)expression of a tumor antigen combined with MHC class I was observed. These results indicate that a multiepitope vaccine, comprising these antigens, could serve as a universal therapeutic vaccine for the vast majority of ovarian cancer patients.
authors.affiliation: Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
authors.forename: Renee
authors.initials: R
authors.lastname: Vermeij
authors.forename: Toos
authors.initials: T
authors.lastname: Daemen
authors.forename: Geertruida H
authors.initials: GH
authors.lastname: de Bock
authors.forename: Pauline
authors.initials: P
authors.lastname: de Graeff
authors.forename: Ninke
authors.initials: N
authors.lastname: Leffers
authors.forename: Annechien
authors.initials: A
authors.lastname: Lambeck
authors.forename: Klaske A
authors.initials: KA
authors.lastname: ten Hoor
authors.forename: Harry
authors.initials: H
authors.lastname: Hollema
authors.forename: Ate G J
authors.initials: AG
authors.lastname: van der Zee
authors.forename: Hans W
authors.initials: HW
authors.lastname: Nijman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D000954:Antigens, Surface / Q000276:immunology / Q000378:metabolism; D002148:Calmodulin-Binding Proteins; D019496:Cancer Vaccines / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology / Q000378:metabolism; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy; D051034:Inhibitor of Apoptosis Proteins; D008565:Membrane Proteins / Q000276:immunology / Q000378:metabolism; D046228:Microarray Analysis; D008869:Microtubule-Associated Proteins / Q000276:immunology / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D000077022:Survivin; D016159:Tumor Suppressor Protein p53 / Q000276:immunology / Q000378:metabolism; D025721:WT1 Proteins / Q000276:immunology / Q000378:metabolism; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; C107489:BIRC5 protein, human; C104948:CTAG1B protein, human; D002148:Calmodulin-Binding Proteins; D019496:Cancer Vaccines; D002352:Carrier Proteins; D015395:Histocompatibility Antigens Class I; D051034:Inhibitor of Apoptosis Proteins; D008565:Membrane Proteins; D008869:Microtubule-Associated Proteins; C090172:SPA17 protein, human; D000077022:Survivin; D016159:Tumor Suppressor Protein p53; D025721:WT1 Proteins